Effect of Pembrolizumab (Keytruda®) on Biomarkers Related to Intratumoral Immunity, Proliferation and Apoptosis in Early ER/PR Negative Breast Cancer.
Phase of Trial: Phase 0
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Early breast cancer; Male breast cancer
- Focus Biomarker; Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 23 Apr 2018 Status changed from not yet recruiting to recruiting.
- 24 Oct 2017 Planned initiation date changed from 1 Jul 2017 to 1 Nov 2017.